Impacted: Prime's mid-market book of business

Please be advised, Prime Therapeutics (Prime) will remove Glucagon-like peptide-1 (GLP-1) medications from our standard maintenance (Rx90) list used by mid-market clients effective Feb. 1, 2025.  

Overview 

This change comes as a result of several network pharmacies, such as Walgreens, limiting the availability of three-month supplies of GLP-1 medications due to increased patient demand and industry-wide supply constraints.  

Members affected by cost share changes may receive written communication. Other benefit designs resulting in a change for the member (e.g. filling a 30-day supply instead of a 90-day supply) may be handled at the pharmacy. 

Rx90 Maintenance drug lists contain products that target specific, chronic conditions that require medications to be taken on a regular ongoing basis to achieve better medical outcomes. This list may also be used to administer client-specific benefits and is not necessarily used by all clients  

Please note, while Prime continues to look for opportunities to optimize client financials, this significant market change may shift financials or rebates per script performance and trigger an equitable adjustment to rebate guarantees based upon individual client contracts. 

Next steps 

There is no action required by clients at this time. Prime will continue to monitor GLP-1 supply constraints and will provide further updates as this situation develops.  

For questions, please reach out to your Prime client account team representative.